Assessing Celcuity (CELC) Valuation After Wells Fargo Coverage And Key FDA NDA Review Progress

Celcuity (CELC) is back in focus after Wells Fargo initiated research coverage and the company filed an omnibus shelf registration covering common and preferred stock, warrants, debt securities, and units.

See our latest analysis for Celcuity.

Those catalysts come on top of a 126.77% 90 day share price return and a very large 1 year total shareholder return, suggesting momentum has been building as investors reassess Celcuity’s prospects and risk profile.

If this kind of biotech story has your attention, it could be a good moment to look at other healthcare stocks that are attracting interest for their pipelines and clinical milestones.

With Celcuity shares up sharply over the past year and trading near a US$110.50 analyst price target, while intrinsic value estimates suggest a wide discount, the key question is whether upside remains or if the market already reflects future growth.

Price-to-Book of 42.5x: Is It Justified?

On P/B, Celcuity screens as very expensive, with the shares at US$107.51 and a 42.5x multiple that sits well above peers and the wider US biotech group.

P/B compares a company’s market value to its book value. For a clinical stage biotech with minimal revenue and ongoing losses, a high ratio usually reflects expectations that future assets and cash flows will matter far more than today’s balance sheet.

For Celcuity, that 42.5x P/B stands against an industry average of 2.7x and a peer average of 7.4x. This is a wide gap that suggests the market is pricing in a much richer future than for many comparable names.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 42.5x (OVERVALUED)

However, that rich P/B, combined with a clinical stage profile with no revenue and a US$162.72m net loss, means any clinical or funding setback could quickly challenge today’s optimism.

Find out about the key risks to this Celcuity narrative.

Another View: DCF Points the Other Way

While the 42.5x P/B ratio makes Celcuity look very expensive versus biotech peers, our DCF model tells a different story. On that view, the shares at US$107.51 sit about 79.9% below an estimated fair value of US$534.72. This implies a large margin between price and intrinsic value.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celcuity for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 882 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Celcuity Narrative

If you see the numbers differently or prefer to test your own assumptions, you can build a personalised Celcuity view in just a few minutes: Do it your way

A great starting point for your Celcuity research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Celcuity has you thinking about what else might be worth your time, do not stop here, the next idea you miss could matter most.

• Spot early stage opportunities by checking out these 3539 penny stocks with strong financials that already show solid financial underpinnings instead of just hype.
• Tap into the AI trend with these 28 AI penny stocks that combine cutting edge themes with detailed fundamental data you can inspect in minutes.
• Zero in on potential mispricings using these 882 undervalued stocks based on cash flows that screen for stocks priced below their estimated cash flow value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com